Inclusion Criteria:

- Diagnosis of MM, NHL, or HD in partial response (PR) or complete response (CR)

- Eligible and planned for an autologous haematopoietic stem cell transplantation

- Written informed consent

- At least 18 years of age (inclusive)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- White blood cell (WBC) count ≥2.5 x 10^9/L

- Absolute neutrophil count (ANC) ≥1.5 x 10^9 /L

- Platelet count ≥100 x 10^9/L

- Serum creatinine ≤2.2 mg/dL

- Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT),
alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), and total
bilirubin <2.5 x upper limit of normal (ULN)

- Adequate cardiac, renal, and pulmonary function sufficient to undergo apheresis and
transplantation, i.e., eligible by institutional standards for autologous stem cell
transplant

- All patients must agree to use a highly effective method of contraception whilst on
study treatment and for at least 3 months following plerixafor treatment (including
both female patients of child-bearing potential and male patients with partners of
child-bearing potential). Effective birth control includes: a) birth control pills,
depot progesterone, or an intrauterine device plus one barrier method, or b) two
barrier methods. Effective barrier methods are: male and female condoms, diaphragms,
and spermicides (creams or gels that contain a chemical to kill sperm). For patients
using a hormonal contraceptive method, information about any interaction of
plerixafor with hormonal contraceptives is not known.

Exclusion Criteria:

- History of any acute or chronic leukaemia (including myelodysplastic syndrome)

- Prior allogeneic transplantation or more than one prior autologous transplantation

- Failed previous CD34+ cell collection attempts (either due to insufficient yield in
apheresis product, or ineligible for apheresis because of inadequate mobilisation of
CD34+ cells into peripheral blood)

- Less than 4 weeks since last anti-cancer therapy (including chemotherapy,
biologic/immunologic, radiation) or less than 6 weeks if prior therapy with
nitrosourea or mitomycin (for therapies with long-acting agents, a treatment-free
interval of at least 2 half-lives should be considered) with the exception of ;
Treatment with thalidomide, dexamethasone, lenalidomide (Revlimid®), and/or
bortezomib (Velcade®) which is allowed up to 7 days prior to the first dose of G-CSF.

- Bone marrow involvement >20% assessed based on the most recent bone marrow aspirate
or biopsy

- Treated with G-CSF or other cytokine within 14 days prior to the first dose of G-CSF
for mobilisation

- Known to be human immunodeficiency virus (HIV) positive

- Active hepatitis B or hepatitis C

- Acute infection (febrile, i.e., temperature >38°C) within 24 hours prior to dosing or
antibiotic therapy within 7 days prior to the first dose of G-CSF

- Hypercalcaemia as evidenced by >1 mg/dL above ULN

- Previously received investigational therapy within 4 weeks of enrolling in this
protocol or currently enrolled in another investigational protocol during the
mobilisation phase

- Central nervous system involvement including brain metastases or leptomeningeal
disease

- Pregnant or nursing women

- Electrocardiogram (ECG) or study result (exercise study, scan) indicative of cardiac
ischaemia or a history of clinically significant rhythm disturbance (arrhythmias), or
other conduction abnormality in the last year that in the opinion of the Investigator
warrants exclusion of the subject from the trial.

- Co-morbid condition(s), which in the opinion of the Investigator, renders the patient
at high risk from treatment complications or impairs their ability to comply with the
study treatment and protocol